Thetis Pharmaceuticals is a clinical-stage biopharmaceutical company developing TP-317, an oral Resolvin E1 drug, for treating mild-to-moderate inflammatory bowel disease (IBD) and solid tumors.  The drug is a first-in-class, oral small molecule agonist of BLT1.

Thetis Pharmaceuticals

Pound Sterling

Squarespace Hosted

Co-Founder, President & Chief Scientific Officer

Frank Sciavolino

Co-Founder and CEO

Gary Mathias

Risk, Safety, Compliance

Timothy Kachmar

Walter C. Ogier

Walter Ogier

Ronald Lennox

Dennis Willson

Elena A. Prokupets

Co-Founder, President, and Chief Scientific Officer

Co-Founder and Chief Executive Officer

Saint John's University - Peter J. Tobin College of Business Alumni Founded Companies

Medical Companies With Fewer Than 10 Employees (Top 10K)

Biotechnology Companies With Less Than $10M in Revenue (Top 10K)

Biotechnology Companies With Less Than $50M in Revenue (Top 10K)

Thetis Pharmaceuticals LLC is a biopharmaceutical company developing novel small molecule drugs to treat inflammatory diseases.

The Leona M. and Harry B. Helmsley Charitable Trust

Grant - Thetis Pharmaceuticals

National Institutes of Health

Venture Round - Thetis Pharmaceuticals

Debt Financing - Thetis Pharmaceuticals

Seed Round - Thetis Pharmaceuticals

Computer and Software Services and Scientific Services

Ridgefield

Connecticut

United States

North America

Cyclodextrin complexes of specialized proresolving mediators

Compositions and methods for cancer therapy

Compositions and methods relating to salts of specialized pro-resolving …

Final Preclinical Data on Thetis’ TP-113 Showing Reduced Insulin Resistance Presented at ICCR

Pakistan

Asia

HTML5

Modernizr

Google Fonts

F5 NGINX

DigiCert

Google Compute Engine

Wordpress

Bootstrap

Google Analytics

jQuery

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

network_onboarding

company_summary

regulatory_analysis

industry_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

logo

swot_analysis

financial_analysis

news_advanced

purchaser_profile

news_impact_assignment_advanced

signals

news_processing_advanced

financial_statements

private_financials

funding_rounds_analysis

company_structure

crunchbase_trigger

crunchbase_profile

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general
public peers	general	Oct 27, 2024 1:01 PM	1d46b03b
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
news advanced	general
news impact assignment advanced	general
signals	general	Oct 27, 2024 1:01 PM	cd874f34
news processing advanced	general
crunchbase trigger	general	Oct 27, 2024 1:01 PM	0eb9679d
crunchbase profile	general	Oct 28, 2024 1:05 PM	3329ec37
peers	general	Oct 27, 2024 1:01 PM	ad0bb1c5
news basic	general	Oct 27, 2024 1:01 PM	8725273f
events	markdown
bundesanzeiger	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis
funding rounds analysis	company_analysis	Oct 27, 2024 1:01 PM	23550cea
company structure	company_analysis
logo	meta	Oct 27, 2024 1:01 PM	628646bf
purchaser profile	merger_acquisitions
private financials	financials
customer profile	customers

THET

COM:THETISPHARMA

Thetis Pharmaceuticals